Epidermal growth factor receptor mutation‐specific immunohistochemical antibodies in lung adenocarcinoma
Histopathology2013Vol. 64(6), pp. 826–839
Citations Over TimeTop 10% of 2013 papers
Ghassan Allo, Bizhan Bandarchi, Naoki Yanagawa, Ami Wang, Warren Shih, Jing Xu, Matthew J. Dalby, Hiroaki Nitta, Christine To, Ni Liu, Jenna Sykes, Ming‐Sound Tsao
Abstract
Immunohistochemistry using EGFR mutant-specific antibodies may be useful in shortening the diagnostic time of lung adenocarcinoma with most common EGFR mutations, especially in samples with low tumour cellularity.
Related Papers
- → Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib(2004)11,455 cited
- → Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response(2008)319 cited
- → Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow(2004)73 cited
- → Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy(2006)37 cited
- [Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].(2011)